About DBIS   | Story archive   | Contact DBIS  | DBIS home

Help for Multiple Sclerosis Victims

Neurologists Study Experimental Drug for Multiple Sclerosis, Patients' Walking and Leg Movement Improves

November 1, 2009

In clinical trials, neurologists found that a drug called Fampridine improves walking abilities in some individuals with Multiple Sclerosis (MS). A disease of the immune system, MS triggers the release of potassium which attacks myelin, a fatty tissue of the nervous system enshrouding the axons connecting nerve cells and passing electrical impulses. The loss of myelin interrupts, delays or disconnects signals between cells. The drug works by enhancing signal-transmission in the nervous system by blocking potassium-ion channels, which serve as entryways on the surfaces of cells, regulating normal electrical activity. Because the drug enhances the way these damaged areas function, patients see an improvement in their leg movement.

read the full story...

Science Insider

ABOUT MULTIPLE SCLEROSIS: Multiple Sclerosis is a disease in which the immune system attacks the central nervous system. It affects the cells that allow the nerve cells in the body and brain to communicate with each other. The immune system attacks the protective myelin which sheaths the nerve cells. The cause of the disease is not currently well understood. The disease takes many forms, and can be progressive or relapsing. It can cause physical and cognitive disabilities. There is no known cure.

ABOUT FAMPRIDINE: Most current drugs used to treat multiple sclerosis target the immune system and the response that strips the myelin that protects axon nerve fibers like the insulation on electrical wire. When stripped, the nerve fibers are exposed and they release potassium, making it harder for the axons to send electrical signals throughout the central nervous system. Fampridine works differently -- it holds potassium in the axon nerve fibers, keeping the communication lines between the brain and the body open.

The American Association of Pharmaceutical Scientists contributed to the information contained in the TV portion of this report.

Video help

Latest stories

  • A Satellite Named Violet and a Student Named Amanda
  • Behind the Scenes with the K-Team
  • Deep Space Discoveries
  • Dogs Fighting Cancer
  • Earthquake! What's Your Risk

More information on this story

Information about MS

To Go Inside This Science:
Andrew D. Goodman, M.D.
University of Rochester Medical Center
Rochester, NY 14642
phone 585-273-1184
e-mail andrew_goodman@urmc.rochester.edu

American Association of Pharmaceutical Scientists
Joseph Catapano
Communications Specialist
catapanoj@aaps.org
703-248-4772



© 2011 American Institute of Physics